Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing notable growth in its Auryon product line, particularly within outpatient-based laboratories (OBLs) and hospitals, which is contributing positively to its average selling prices (ASP). The company is on track to enhance its gross margin (GM) to 52.5% by accelerating manufacturing initiatives and benefiting from a favorable shift towards higher-margin Med-Tech revenues. Additionally, ongoing customer acquisition, increased utilization in existing accounts, and successful pricing strategies indicate strong future growth potential for its key products.

Bears say

AngioDynamics, Inc. anticipates $4M-$6M in tariff headwinds, which could negatively impact their financial performance. The company also projects inventory pressures in the second half of fiscal year 2026 due to rising raw material costs, further affecting profitability. Despite a strong performance in capital sales for NanoKnife disposables, these external challenges could undermine future growth and demand for the company's medical devices.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.